Skip to content

Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study

WISE Ancillary Study Data Analyses: Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00600106
Enrollment
37
Registered
2008-01-24
Start date
1999-12-31
Completion date
2010-03-31
Last updated
2019-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Ischemia

Brief summary

The goal of the main trial was to evaluate the effect of low dose hormone replacement therapy with 1 mg norethindrone/10mcg ethinyl estradiol in postmenopausal women with a history of chest discomfort, myocardial ischemia and no obstructive CAD. For the purposes of this study as a core lab coordinating center, the investigators will be performing P31 MRS core lab analyses; hormone core lab analyses; lipid core lab analyses; glucose, insulin and HOMA core lab analyses; exercise stress test/Holter monitor core lab analyses; brachial artery reactivity test core lab analyses; full study data analyses for manuscript preparation and the writing and submission and publication of manuscript. The main trial duration: December 1999 - May 2003. The ancillary data analysis project duration: April 2006 - March 2010.

Detailed description

See Brief Summary above.

Interventions

DRUG1/10 NA/EE

Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)

DRUGPlacebo

1 mg placebo

Sponsors

Parke-Davis
CollaboratorINDUSTRY
University of Pittsburgh
CollaboratorOTHER
University of Florida
CollaboratorOTHER
Allegheny University
CollaboratorUNKNOWN
University of Alabama at Birmingham
CollaboratorOTHER
Johns Hopkins University
CollaboratorOTHER
Cedars-Sinai Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Postmenopausal WISE and nonWISE study participants * Normal/minimally diseased coronary arteries (\<50% luminal diameter stenosis in all epicardial coronary arteries) within 36 months of ancillary study entry and no intercurrent MI, PTCA, CABG * Any one (or multiple) of the following criteria suggestive of myocardial ischemia within 36 months of ancillary study entry: 1. Abnormal P-31 magnetic resonance spectroscopy (a fall in quantitative PCr/ATP ratio \>15% from control) performed at a WISE or nonWISE site 2. Positive exercise stress test (\> or = 1mm horizontal or downsloping, or \> or =1.5mm upsloping ST segment depression measured 0.08 msec after the J point), performed and/or interpretated by a WISE or WISE ancillary ancillary trial investigator 3. Reversible stress radionuclide perfusion defect \> equivocal and not attributable to breast/imaging artifact. performed as part of the WISE protocol 4. Coronary artery flow reserve \<2.25 performed. as part of using the WISE protocol * No contraindications to 12 weeks of FemHRT or hormone replacement therapy * Normal mammogram and pelvic exam (including PAP smear for those with an intact uterus) within 12 months of study entry * Documented normal liver function testing (SGOT) within 3 months of study entry.

Exclusion criteria

* Documented myocardial infarction, coronary artery bypass surgery or mechanical revascularization * Systolic blood pressure \>200 mmHg or diastolic blood pressure \>105 mmHg * LDL-cholesterol \>190 mg/dl, triglycerides \> or = 300 mg/dl * Clinically significant hepatic or renal dysfunction (SGOT more than 1.2 times normal at baseline, serum creatinine \>2) * Uncontrolled diabetes mellitus (FBS \> or = 225 mg/dl) or new onset diabetes until stabilized * Clinically significant valvular heart disease, dilated cardiomyopathy, or congestive heart failure (NYHA Class IV or severe Class III) * Currently on hormone replacement therapy and unwilling/unable to withdraw treatment prior to study, (participants are eligible for study entry 4-8 weeks following hormone replacement therapy withdrawal, at the discretion of the WISE ancillary trial Principal Investigator) * Previous breast cancer, mammogram suggestive of cancer, or endometrial cancer without hysterectomy * Abnormal uterine bleeding or abnormal Pap smear (SIL I, II or III, carcinoma in situ, or cancer) * Previous deep venous thrombosis, pulmonary embolism, or other thromboembolic disorder. * Alcoholism or drug abuse * Participation in any other investigational drug or device study Women with elevated diastolic (\> or = 90 mm Hg) or systolic (\> or = 140 mm Hg) blood pressure, LDL-cholesterol (\> or = 160 mg/dl), fasting blood sugar (\> or = 130 mg/dl) and women who smoke cigarettes will be told their risk factor levels and referred for evaluation and treatment by their private physician.

Design outcomes

Primary

MeasureTime frameDescription
Inducible Myocardial IschemiaBaselineInducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-\[average of rest and recovery periods\]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio \>20% from rest, and a lower value is considered indicative of greater ischemia.
Endothelial Dysfunction (FMD)BaselineEndothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction. Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter \[diameter after cuff deflation - baseline diameter / baseline diameter) x 100\].

Secondary

MeasureTime frameDescription
Quality of Life - Health SurveyBaselineQuality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Physical Functional Disability - Functional Capacity (Metabolism Equivalents)BaselinePhysical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.
Physical Functional Disability - Functional Capacity (METs)BaselinePhysical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on.
Physical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression)Exit (12 weeks)Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (\>1.0 mm horizontal / downsloping or \>1.5 upsloping ST segment depression measured 0.08 msec after the J point).
Physical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression)BaselinePhysical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (\>1.0 mm horizontal / downsloping or \>1.5 upsloping ST segment depression measured 0.08 msec after the J point).
Quality of Life - Menopause SymptomsBaselineQuality of life assessed by menopausal symptoms and psychological questionnaires

Countries

United States

Participant flow

Participants by arm

ArmCount
Hormone Replacement Therapy
Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE).
18
Placebo
1 mg placebo.
19
Total37

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject11

Baseline characteristics

CharacteristicHormone Replacement TherapyTotalPlacebo
Age, Continuous56 years
STANDARD_DEVIATION 9
57.5 years
STANDARD_DEVIATION 8
59 years
STANDARD_DEVIATION 7
Body Mass Index31 kg/m^2
STANDARD_DEVIATION 9
31 kg/m^2
STANDARD_DEVIATION 8
31 kg/m^2
STANDARD_DEVIATION 7
Current HT use prior to entry
Current HT use prior to entry
6 participants14 participants8 participants
Current HT use prior to entry
No HT prior to entry
12 participants23 participants11 participants
Current Smoking
No smoking
16 participants33 participants17 participants
Current Smoking
Smoking
2 participants4 participants2 participants
Diastolic Blood Pressure76 mmHg
STANDARD_DEVIATION 13
77 mmHg
STANDARD_DEVIATION 11
78 mmHg
STANDARD_DEVIATION 9
Education
College
8 participants14 participants6 participants
Education
High school or less
10 participants23 participants13 participants
Fasting Blood Sugar93 mg/dl
STANDARD_DEVIATION 17
93.5 mg/dl
STANDARD_DEVIATION 18.5
94 mg/dl
STANDARD_DEVIATION 20
HDL-Cholesterol48 mg/dl
STANDARD_DEVIATION 16
51 mg/dl
STANDARD_DEVIATION 12.5
54 mg/dl
STANDARD_DEVIATION 9
History of Diabetes
History of Diabetes
4 participants9 participants5 participants
History of Diabetes
No Diabetes
14 participants28 participants14 participants
History of Dyslipidemia
Dyslipidemia
11 participants18 participants7 participants
History of Dyslipidemia
Normal values
7 participants19 participants12 participants
History of Hypertension
Hypertension
5 participants19 participants14 participants
History of Hypertension
Normal blood pressure
13 participants18 participants5 participants
LDL-Cholesterol120 mg/dl
STANDARD_DEVIATION 51
122 mg/dl
STANDARD_DEVIATION 44.5
124 mg/dl
STANDARD_DEVIATION 38
Pulse68 beats per minute
STANDARD_DEVIATION 8
72 beats per minute
STANDARD_DEVIATION 9.5
76 beats per minute
STANDARD_DEVIATION 11
Race/Ethnicity, Customized
Nonwhite
3 participants6 participants3 participants
Race/Ethnicity, Customized
White
15 participants31 participants16 participants
Sex: Female, Male
Female
18 Participants37 Participants19 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
Systolic Blood Pressure130 mmHg
STANDARD_DEVIATION 18
133 mmHg
STANDARD_DEVIATION 18
136 mmHg
STANDARD_DEVIATION 18
Total Cholesterol195 mg/dl
STANDARD_DEVIATION 47
200 mg/dl
STANDARD_DEVIATION 43
205 mg/dl
STANDARD_DEVIATION 39
Triglycerides132 mg/dl
STANDARD_DEVIATION 92
133 mg/dl
STANDARD_DEVIATION 78
134 mg/dl
STANDARD_DEVIATION 64
Waist circumference92 cm.
STANDARD_DEVIATION 17
92.5 cm.
STANDARD_DEVIATION 16
93 cm.
STANDARD_DEVIATION 15

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 180 / 19
serious
Total, serious adverse events
2 / 180 / 19

Outcome results

Primary

Endothelial Dysfunction (FMD)

Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction. Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter \[diameter after cuff deflation - baseline diameter / baseline diameter) x 100\].

Time frame: Baseline

Population: Brachial artery reactivity testing at baseline by treatment

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyEndothelial Dysfunction (FMD)8.2 percentage of pre-stimulus diameterStandard Deviation 7.8
PlaceboEndothelial Dysfunction (FMD)8.8 percentage of pre-stimulus diameterStandard Deviation 7.3
Comparison: Data were presented in tables as means and SDs for continuous variables and frequencies for categorical variables. Comparisons between the placebo and 1/10 NA/EE groups were don using Wilcoxon rank sum test for continuous measurement and Fisher's exact test for discrete data. The strategy of analysis was intention to treat with comparing the study groups in term of treatment to which they were randomly allocated.p-value: 0.77Wilcoxon rank sum test
Primary

Endothelial Dysfunction (FMD)

Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function. Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter \[diameter after cuff deflation - baseline diameter / baseline diameter) x 100\].

Time frame: 12 weeks

Population: Brachial artery reactivity testing at study exit by treatment

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyEndothelial Dysfunction (FMD)8.8 percentage of pre-stimulus diameterStandard Deviation 5.3
PlaceboEndothelial Dysfunction (FMD)7.3 percentage of pre-stimulus diameterStandard Deviation 6.1
Comparison: Data were presented in tables as means and SDs for continuous variables and frequencies for categorical variables. Comparisons between the placebo and 1/10 NA/EE groups were don using Wilcoxon rank sum test for continuous measurement and Fisher's exact test for discrete data. The strategy of analysis was intention to treat with comparing the study groups in term of treatment to which they were randomly allocated.p-value: 0.38Wilcoxon rank sum test
Primary

Inducible Myocardial Ischemia

Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-\[average of rest and recovery periods\]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio \>20% from rest, and a lower value is considered indicative of greater ischemia.

Time frame: 12 weeks

Population: Among the 35 women, 28 baseline and 26 exit MRS results were technically adequate for spectral analyses with rest, handgrip exercise, and recovery spectra. A total of 24 women (13 drug, 11 placebo) had both baseline and exit P31's.

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyInducible Myocardial Ischemia-7.7 percent change in PCR/ATP ratioStandard Deviation 20.8
PlaceboInducible Myocardial Ischemia1.1 percent change in PCR/ATP ratioStandard Deviation 9.7
Comparison: Data were presented in tables as means and SDs for continuous variables and frequencies for categorical variables. Comparisons between the placebo and 1/10 NA/EE groups were don using Wilcoxon rank sum test for continuous measurement and Fisher's exact test for discrete data. The strategy of analysis was intention to treat with comparing the study groups in term of treatment to which they were randomly allocated. All tests were two-sided with p values \<0.05.p-value: 0.17t-test (nonparametric Wilcoxon test)
Primary

Inducible Myocardial Ischemia

Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-\[average of rest and recovery periods\]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio \>20% from rest, and a lower value is considered indicative of greater ischemia.

Time frame: Baseline

Population: Among the 35 women, 28 baseline and 26 exit MRS results were technically adequate for spectral analyses with rest, handgrip exercise, and recovery spectra. A total of 24 women (13 drug, 11 placebo) had both baseline and exit P31's.

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyInducible Myocardial Ischemia-13.8 percent changed in PCR/ATP ratioStandard Deviation 24.2
PlaceboInducible Myocardial Ischemia-7.0 percent changed in PCR/ATP ratioStandard Deviation 22.8
Comparison: Data were presented in tables as means and SDs for continuous variables and frequencies for categorical variables. Comparisons between the placebo and 1/10 NA/EE groups were don using Wilcoxon rank sum test for continuous measurement and Fisher's exact test for discrete data. The strategy of analysis was intention to treat with comparing the study groups in term of treatment to which they were randomly allocated.p-value: 0.36t-test (nonparametric Wilcoxon test)
Secondary

Physical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (\>1.0 mm horizontal / downsloping or \>1.5 upsloping ST segment depression measured 0.08 msec after the J point).

Time frame: Baseline

Population: Exercise stress testing at baseline by treatment

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyPhysical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression)-0.79 mmStandard Deviation 0.78
PlaceboPhysical Functional Disability - Functional Capacity (Exercise Induced ST Segment Depression)-0.79 mmStandard Deviation 0.47
p-value: 0.99Wilcoxon rank sum test
Secondary

Physical Functional Disability - Functional Capacity (Metabolism Equivalents)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.

Time frame: Exit (12 weeks)

Population: Exercise stress testing at exit (12 weeks) by treatment

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyPhysical Functional Disability - Functional Capacity (Metabolism Equivalents)6.1 metabolism equivalentsStandard Deviation 2.4
PlaceboPhysical Functional Disability - Functional Capacity (Metabolism Equivalents)5.4 metabolism equivalentsStandard Deviation 2.5
p-value: 0.4Wilcoxon rank sum test
Secondary

Physical Functional Disability - Functional Capacity (Metabolism Equivalents)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.

Time frame: Baseline

Population: Exercise stress testing at baseline by treatment

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyPhysical Functional Disability - Functional Capacity (Metabolism Equivalents)6.1 metabolism equivalentsStandard Deviation 3
PlaceboPhysical Functional Disability - Functional Capacity (Metabolism Equivalents)5.8 metabolism equivalentsStandard Deviation 2.1
p-value: 0.77Wilcoxon rank sum test
Secondary

Physical Functional Disability - Functional Capacity (METs)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on.

Time frame: Baseline

Population: Exercise stress testing at baseline by treatment

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyPhysical Functional Disability - Functional Capacity (METs)5.4 metabolism equivalentsStandard Deviation 2.6
PlaceboPhysical Functional Disability - Functional Capacity (METs)5.4 metabolism equivalentsStandard Deviation 1.8
p-value: 0.93Wilcoxon rank sum test
Secondary

Physical Functional Disability - Functional Capacity (METs)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on.

Time frame: Exit at 12 weeks

Population: Exercise stress testing at exit (12 weeks) by treatment

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyPhysical Functional Disability - Functional Capacity (METs)6.1 metabolism equivalentsStandard Deviation 2.4
PlaceboPhysical Functional Disability - Functional Capacity (METs)5.4 metabolism equivalentsStandard Deviation 2.5
p-value: 0.49Wilcoxon rank sum test
Secondary

Physical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression)

Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (\>1.0 mm horizontal / downsloping or \>1.5 upsloping ST segment depression measured 0.08 msec after the J point).

Time frame: Exit (12 weeks)

Population: Exercise stress testing at exit (12 weeks) by treatment

ArmMeasureValue (MEAN)Dispersion
Hormone Replacement TherapyPhysical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression)-1.05 mmStandard Deviation 0.98
PlaceboPhysical Functional Disability - Functional Capacity (Stress Induced ST Segment Depression)-0.63 mmStandard Deviation 0.29
p-value: 0.21Wilcoxon rank sum test
Secondary

Quality of Life - Health Survey

Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Time frame: 12 weeks

Population: SF-36 scale at exit by treatment

ArmMeasureGroupValue (MEAN)Dispersion
Hormone Replacement TherapyQuality of Life - Health SurveyPhysical functioning59.4 units on a scaleStandard Deviation 23.5
Hormone Replacement TherapyQuality of Life - Health SurveyRole-physical58.8 units on a scaleStandard Deviation 37.4
Hormone Replacement TherapyQuality of Life - Health SurveyRole-emotional76.5 units on a scaleStandard Deviation 34.9
Hormone Replacement TherapyQuality of Life - Health SurveyBodily pain54.5 units on a scaleStandard Deviation 23.6
Hormone Replacement TherapyQuality of Life - Health SurveyGeneral health55.2 units on a scaleStandard Deviation 19.7
Hormone Replacement TherapyQuality of Life - Health SurveyMental health66.4 units on a scaleStandard Deviation 19.6
Hormone Replacement TherapyQuality of Life - Health SurveyVitality35.6 units on a scaleStandard Deviation 24.5
Hormone Replacement TherapyQuality of Life - Health SurveySocial functioning59.4 units on a scaleStandard Deviation 16
PlaceboQuality of Life - Health SurveySocial functioning56.1 units on a scaleStandard Deviation 20.6
PlaceboQuality of Life - Health SurveyPhysical functioning44.4 units on a scaleStandard Deviation 29.5
PlaceboQuality of Life - Health SurveyGeneral health57.2 units on a scaleStandard Deviation 15.8
PlaceboQuality of Life - Health SurveyRole-physical25.0 units on a scaleStandard Deviation 33.2
PlaceboQuality of Life - Health SurveyVitality41.2 units on a scaleStandard Deviation 18
PlaceboQuality of Life - Health SurveyRole-emotional66.7 units on a scaleStandard Deviation 39.6
PlaceboQuality of Life - Health SurveyMental health69.3 units on a scaleStandard Deviation 18.8
PlaceboQuality of Life - Health SurveyBodily pain41.5 units on a scaleStandard Deviation 21.6
Secondary

Quality of Life - Health Survey

Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Time frame: Baseline

Population: SF-36 scale at baseline by treatment

ArmMeasureGroupValue (MEAN)Dispersion
Hormone Replacement TherapyQuality of Life - Health SurveyPhysical functioning60.8 units on a scaleStandard Deviation 27.5
Hormone Replacement TherapyQuality of Life - Health SurveyRole-physical54.2 units on a scaleStandard Deviation 41.3
Hormone Replacement TherapyQuality of Life - Health SurveyRole-emotional70.3 units on a scaleStandard Deviation 42.6
Hormone Replacement TherapyQuality of Life - Health SurveyBodily pain53.3 units on a scaleStandard Deviation 21.4
Hormone Replacement TherapyQuality of Life - Health SurveyGeneral health55.4 units on a scaleStandard Deviation 19.4
Hormone Replacement TherapyQuality of Life - Health SurveyMental health66.7 units on a scaleStandard Deviation 20.6
Hormone Replacement TherapyQuality of Life - Health SurveyVitality35.6 units on a scaleStandard Deviation 23.1
Hormone Replacement TherapyQuality of Life - Health SurveySocial functioning59.4 units on a scaleStandard Deviation 14.7
PlaceboQuality of Life - Health SurveySocial functioning53.2 units on a scaleStandard Deviation 24.3
PlaceboQuality of Life - Health SurveyPhysical functioning43.8 units on a scaleStandard Deviation 27.4
PlaceboQuality of Life - Health SurveyGeneral health57.4 units on a scaleStandard Deviation 15.1
PlaceboQuality of Life - Health SurveyRole-physical37.3 units on a scaleStandard Deviation 40.2
PlaceboQuality of Life - Health SurveyVitality42.9 units on a scaleStandard Deviation 20.4
PlaceboQuality of Life - Health SurveyRole-emotional66.7 units on a scaleStandard Deviation 41.6
PlaceboQuality of Life - Health SurveyMental health65.7 units on a scaleStandard Deviation 19.9
PlaceboQuality of Life - Health SurveyBodily pain42.1 units on a scaleStandard Deviation 17.4
Secondary

Quality of Life - Menopause Symptoms

Quality of life assessed by menopausal symptoms and psychological questionnaires

Time frame: 12 weeks

Population: Menopause Symptoms at exit by treatment

ArmMeasureGroupValue (NUMBER)
Hormone Replacement TherapyQuality of Life - Menopause SymptomsPoor memory59 percent of participants
Hormone Replacement TherapyQuality of Life - Menopause SymptomsVaginal dryness35 percent of participants
Hormone Replacement TherapyQuality of Life - Menopause SymptomsHot flushes or flashing41 percent of participants
Hormone Replacement TherapyQuality of Life - Menopause SymptomsAvoiding intimacy24 percent of participants
Hormone Replacement TherapyQuality of Life - Menopause SymptomsChange in sexual desire35 percent of participants
PlaceboQuality of Life - Menopause SymptomsAvoiding intimacy56 percent of participants
PlaceboQuality of Life - Menopause SymptomsPoor memory78 percent of participants
PlaceboQuality of Life - Menopause SymptomsChange in sexual desire67 percent of participants
PlaceboQuality of Life - Menopause SymptomsVaginal dryness67 percent of participants
PlaceboQuality of Life - Menopause SymptomsHot flushes or flashing89 percent of participants
Secondary

Quality of Life - Menopause Symptoms

Quality of life assessed by menopausal symptoms and psychological questionnaires

Time frame: Baseline

Population: Menopause Symptoms at baseline by treatment

ArmMeasureGroupValue (NUMBER)
Hormone Replacement TherapyQuality of Life - Menopause SymptomsPoor memory76 percent of participants
Hormone Replacement TherapyQuality of Life - Menopause SymptomsVaginal dryness44 percent of participants
Hormone Replacement TherapyQuality of Life - Menopause SymptomsChange in sexual desire50 percent of participants
Hormone Replacement TherapyQuality of Life - Menopause SymptomsAvoiding intimacy39 percent of participants
Hormone Replacement TherapyQuality of Life - Menopause SymptomsHot flushes or flashing89 percent of participants
PlaceboQuality of Life - Menopause SymptomsAvoiding intimacy37 percent of participants
PlaceboQuality of Life - Menopause SymptomsHot flushes or flashing68 percent of participants
PlaceboQuality of Life - Menopause SymptomsPoor memory53 percent of participants
PlaceboQuality of Life - Menopause SymptomsChange in sexual desire37 percent of participants
PlaceboQuality of Life - Menopause SymptomsVaginal dryness58 percent of participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026